Harpoon Therapeutics, Inc. Contracts & Agreements
56 Contracts & Agreements
- Business Finance (17 contracts)
- Business Operations (10)
- Human Resources (16)
- Intellectual Property (3)
- Mergers & Acquisitions (1)
- Real Estate (3)
- Uncategorized (6)
- Agreement and Plan of Merger, by and among Merck Sharp & Dohme LLC, Harpoon Therapeutics, Inc., and Hawaii Merger Sub, Inc., dated January 7, 2024 (Filed With SEC on January 8, 2024)
- Form of Restricted Stock Unit Award Notice and Agreement, dated November 26, 2023 (Filed With SEC on November 28, 2023)
- Form of Retention Bonus Agreement, dated November 26, 2023 (Filed With SEC on November 28, 2023)
- Form of Registration Rights Agreement (Filed With SEC on October 24, 2023)
- Form of Securities Purchase Agreement (Filed With SEC on October 24, 2023)
- Form of October 2023 Pre-Funded Warrant (Filed With SEC on October 24, 2023)
- Form of October 2023 Warrant to Purchase Common Stock or Pre-Funded Warrants (Filed With SEC on October 24, 2023)
- Registration Rights Agreement, dated March 22, 2023, by and among the Company and the Purchasers (Filed With SEC on March 27, 2023)
- Securities Purchase Agreement, dated March 22, 2023, by and among the Company and the Purchasers (Filed With SEC on March 27, 2023)
- Form of Common Stock Purchase Warrant (Filed With SEC on March 27, 2023)
- Harpoon Therapeutics, Inc. 2019 Equity Incentive Plan and related form agreements (Filed With SEC on August 10, 2022)
- Harpoon Therapeutics, Inc. 2022 Inducement Plan, Form of Stock Option Grant Notice, Option Agreement, Form of Restricted Stock Grant Notice and Restricted Stock Unit Award... (Filed With SEC on June 28, 2022)
- Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on May 12, 2022)
- Employment Offer Letter by and between Julie Eastland and the Registrant dated as of October 25, 2021 (Filed With SEC on May 12, 2022)
- Transition and Retirement Agreement by and between Gerald McMahon and the Registrant, dated as of October 25, 2021 (Filed With SEC on March 10, 2022)
- Harpoon Therapeutics, Inc. South San Francisco, CA (Filed With SEC on March 10, 2022)
- Amendment No. 1 to Amended and Restated Discovery Collaboration and License Agreement by and between the Registrant and AbbVie, Inc., dated as of August 16, 2021 (Filed With SEC on November 10, 2021)
- Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on May 6, 2021)
- Underwriting Agreement, dated January 6, 2021, by and among the Company, SVB Leerink LLC and Piper Sandler & Co., as the Representatives of the several underwriters named therein (Filed With SEC on January 7, 2021)
- First Amendment to the Development and Option Agreement between the Registrant and AbbVie Biotechnology Ltd., dated as of April 21, 2020 (Filed With SEC on August 5, 2020)
- Side Letter Amendment to Development and Option Agreement between the Registrant and AbbVie Biotechnology Ltd., dated April 15, 2020 (Filed With SEC on August 5, 2020)
- Second Amended and Restated Assignment and License Agreement between the Registrant and Werewolf Therapeutics, Inc., dated as of December 20, 2019 (Filed With SEC on March 12, 2020)
- Description of Registrants securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 12, 2020)
- Development and Option Agreement between the Registrant and AbbVie Biotechnology Ltd., dated as of November 20, 2019 (Filed With SEC on March 12, 2020)
- Amended and Restated Discovery Collaboration and License Agreement between the Registrant and AbbVie Biotechnology Ltd., dated as of November 20, 2019 (Filed With SEC on March 12, 2020)
- Fifth Amended and Restated Consulting Agreement by and between Patrick Baeuerle and the Registrant, dated as of March 3, 2020 (Filed With SEC on March 12, 2020)
- First Amendment to the Discovery Collaboration and License Agreement between the Registrant and AbbVie Biotechnology Ltd., dated as of April 3, 2019 (Filed With SEC on May 9, 2019)
- Amendment to CHEF1 Collaboration and License Agreement and Development and Manufacturing Services Agreement between Registrant and AGC Biologics, Inc. (formerly known as CMC ICOS... (Filed With SEC on January 29, 2019)
- Form of Underwriting Agreement (Filed With SEC on January 29, 2019)
- Asset Transfer Agreement by and between Maverick Therapeutics, Inc. and the Registrant, dated as of December 30, 2016, as amended (Filed With SEC on January 29, 2019)
- Form of Common Stock Certificate (Filed With SEC on January 29, 2019)
- 2019 Equity Incentive Plan and forms of grant notice, stock option and restricted stock unit award agreements and notice of exercise thereunder (Filed With SEC on January 29, 2019)
- 2019 Employee Stock Purchase Plan (Filed With SEC on January 29, 2019)
- Non-Employee Director Compensation Policy (Filed With SEC on January 29, 2019)
- Employment Offer Letter by and between Georgia Erbez and the Registrant, dated October 19, 2018 (Filed With SEC on January 4, 2019)
- Form of Indemnity Agreement, by and between the Registrant and its directors and executive officers (Filed With SEC on January 4, 2019)
- Development and Manufacturing Services Agreement between the Registrant and CMC ICOS Biologics, Inc., dated July 5, 2016 (Filed With SEC on December 27, 2018)
- Asset Transfer Agreement by and between Maverick Therapeutics, Inc. and the Registrant, dated as of December 30, 2016, as amended (Filed With SEC on December 27, 2018)
- Amended and Restated Investors Rights Agreement, dated as of November 9, 2018, by and among the Registrant and certain of its stockholders (Filed With SEC on December 27, 2018)
- Warrant to Purchase Common Stock issued on July 13, 2016 to Danforth Advisors, LLC (Filed With SEC on December 27, 2018)
- Form of Warrant to Purchase Common Stock issued to entities affiliated with MPM Capital, Inc. on March 24, 2015, July 23, 2015, August 17, 2015 and December 16, 2015 in connection... (Filed With SEC on December 27, 2018)
- Form of Warrant to Purchase Common Stock issued to entities affiliated with MPM Capital, Inc. and UBS Oncology Impact Fund L.P. on November 1, 2016 and January 10, 2017 in... (Filed With SEC on December 27, 2018)
- 2015 Equity Incentive Plan and forms of grant notice, stock option and restricted stock unit award agreements and notice of exercise thereunder (Filed With SEC on December 27, 2018)
- Lease by and between HCP Oyster Point III LLC and the Registrant, dated as of July 27, 2018 (Filed With SEC on December 27, 2018)
- Lease by and between AP3-SF1 4000 Shoreline, LLC and Tizona Therapeutics, Inc., dated as of December 21, 2015, as amended (Filed With SEC on December 27, 2018)
- Sublease between Tizona Therapeutics, Inc. and the Registrant, dated as of February 6, 2017 (Filed With SEC on December 27, 2018)
- Employment Offer Letter by and between Gerald McMahon and the Registrant, dated December 10, 2016 (Filed With SEC on December 27, 2018)
- CHEF1 Collaboration and License Agreement between the Registrant and CMC ICOS Biologics, Inc., dated October 26, 2015 (Filed With SEC on December 27, 2018)
- First Amended and Restated Assignment and License Agreement between Werewolf Therapeutics, Inc. and the Registrant, dated as of October 19, 2018 (Filed With SEC on December 27, 2018)
- Royalty Transfer Agreement by and between the Registrant, MPM Oncology Charitable Foundation, Inc. and the UBS Optimus Foundation, dated December 1, 2016, as amended (Filed With SEC on December 27, 2018)
- License Agreement between the Registrant and TCR2 Therapeutics, Inc., dated June 21, 2017 (Filed With SEC on December 27, 2018)
- Discovery Collaboration and License Agreement between the Registrant and AbbVie Biotechnology Ltd., dated as of October 10, 2017 (Filed With SEC on December 27, 2018)
- Third Amended and Restated Consulting Agreement dated as of February 1, 2017, by and between the Registrant and Patrick Baeuerle, as amended (Filed With SEC on December 27, 2018)
- Consulting Agreement between the Company and William Picht, Jr., dated September 12, 2018 (Filed With SEC on December 27, 2018)
- Employment Offer Letter by and between Natalie Sacks and the Registrant, dated September 13, 2018 (Filed With SEC on December 27, 2018)
- Employment Offer Letter by and between Holger Wesche and the Registrant, dated March 17, 2015, as amended (Filed With SEC on December 27, 2018)
